Sociodemographics and Comorbidities Influence Decisions to Undergo Pancreatic Resection for Neoplastic Lesions

Journal of Gastrointestinal Surgery

Volumn 14, Issue 9, 2010, Pages 1401-1408

  Sandroussi, Charbel ^a   Brace, Chantelle ^a   Kennedy, Erin D ^a,c   Baxter, Nancy N ^b,c   Gallinger, Steven ^a   Wei, Alice C ^a,c,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Decision making; Neoplasm; Pancreas; Pancreatectomy

Indexed keywords

AGED; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; DECISION MAKING; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PANCREAS RESECTION; PANCREAS TUMOR; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

AGED; COMORBIDITY; DECISION MAKING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 77955846487     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-010-1255-2     Document Type: Article

References (57)

1. Azria D, Ychou M, Jacot W, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas 2002; 25(4): 360-5.
2. Lavu H, Mascaro AA, Grenda DR, et al. Margin positive pancreaticoduodenectomy is superior to palliative bypass in locally advanced pancreatic ductal adenocarcinoma. J Gastrointest Surg 2009; 13: 1937-1946.
3. Okamoto A, Tsuruta K, Karasawa K, et al. Resection versus palliation: treatment of stage III and IVA carcinomas of the pancreas employing intraoperative radiation. World J Surg 2003; 27(5): 599-605.
4. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358(9293): 1576-85.
5. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234(6): 758-68.
6. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350(12): 1200-10.
7. Ramacciato G, Mercantini P, Petrucciani N, et al. Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol 2009; 16(4): 817-25.
8. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. Jama 2008; 299(9): 1019-26.
9. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. Jama 1998; 280(20): 1747-51.
10. Glasgow RE, Jackson HH, Neumayer L, et al. Pancreatic resection in Veterans Affairs and selected university medical centers: results of the patient safety in surgery study. J Am Coll Surg 2007; 204(6): 1252-60.
11. Glasgow RE, Mulvihill SJ. Hospital volume influences outcome in patients undergoing pancreatic resection for cancer. West J Med 1996; 165(5): 294-300.
12. Balcom 4th JH, Rattner DW, Warshaw AL, et al. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001; 136(4): 391-8.
13. Lightner AM, Glasgow RE, Jordan TH, et al. Pancreatic resection in the elderly. J Am Coll Surg 2004; 198(5): 697-706.
14. Petrowsky H, Clavien PA. Should we deny surgery for malignant hepato-pancreatico-biliary tumors to elderly patients? World J Surg 2005; 29(9): 1093-100.
15. Tamijmarane A, Bhati CS, Mirza DF, et al. Application of Portsmouth modification of physiological and operative severity scoring system for enumeration of morbidity and mortality (P-POSSUM) in pancreatic surgery. World J Surg Oncol 2008; 6: 39.
16. Ouellette JR, Small DG, Termuhlen PM. Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg 2004; 8(8): 1061-67.
17. de Castro SM, Biere SS, Lagarde SM, et al. Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas. Br J Surg 2009; 96(4): 417-23.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373-83.
19. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47(11): 1245-51.
20. O'Connor KM, Davis N, Lennon GM, et al. Can we avoid surgery in elderly patients with renal masses by using the Charlson comorbidity index? BJU Int 2008; 103: 1492-1495.
21. Koppie TM, Serio AM, Vickers AJ, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008; 112(11): 2384-92.
22. Dalton SO, Schuz J, Engholm G, et al. Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994-2003: Summary of findings. Eur J Cancer 2008; 44(14): 2074-85.
23. Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002; 162(17): 1985-93.
24. Oliver MN. Access to prostate cancer care and implications for survival among minorities. J Urol 2009; 181(2): 447-8.
25. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol 2006; 24(14): 2179-87.
26. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49(12): 1429-33.
27. Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004; 57(12): 1288-94.
28. Neoptolemos JP, Stocken DD, Tudur Smith C, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009; 100(2): 246-50.
29. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244(1): 10-5.
30. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U. S.: utilization, outcomes, and the effect of hospital volume. Cancer 2007; 110(6): 1227-34.
31. Fernandez-Cruz L, Blanco L, Cosa R, Rendon H. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg 2008; 32(5): 904-17.
32. Casadei R, Ricci C, Zanini N, et al. Laparoscopic distal pancreatectomy in non-malignant pancreatic tumors. Jop 2008; 9(1): 71-3.
33. Eom BW, Jang JY, Lee SE, et al. Clinical outcomes compared between laparoscopic and open distal pancreatectomy. Surg Endosc 2008; 22(5): 1334-8.
34. Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg 2007; 246(2): 173-80.
35. Cress RD, Yin D, Clarke L, et al. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006; 17(4): 403-9.
36. Riall TS, Nealon WH, Goodwin JS, et al. Pancreatic cancer in the general population: improvements in survival over the last decade. J Gastrointest Surg 2006; 10(9): 1212-23; discussion 1223-4.
37. Kondo K, Chijiiwa K, Funagayama M, et al. Hepatic resection is justified for elderly patients with hepatocellular carcinoma. World J Surg 2008; 32(10): 2223-9.
38. Vickers SM, Kerby JD, Smoot TM, et al. Economics of pancreatoduodenectomy in the elderly. Surgery 1996; 120(4): 620-5; discussion 625-6.
39. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006; 10(9): 1199-1210; discussion 1210-1.
40. Finlayson EV, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery: a national study. Arch Surg 2003; 138(7): 721-5; discussion 726.
41. Riall TS, Nealon WH, Goodwin JS, et al. Outcomes following pancreatic resection: variability among high-volume providers. Surgery 2008; 144(2): 133-40.
42. Bilimoria KY, Talamonti MS, Sener SF, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 2008; 207(4): 510-9.
43. Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349(22): 2117-27.
44. Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg 2007; 205(6): 729-34.
45. Rothman MD, van Ness PH, O'Leary JR, Fried TR. Refusal of medical and surgical interventions by older persons with advanced chronic disease. J Gen Intern Med 2007; 22(7): 982-7.
46. Gulbinas A, Barauskas G, Pundzius J. Preoperative stratification of pancreas-related morbidity after the Whipple procedure. Int Surg 2004; 89(1): 39-45.
47. Wang CY, Lin YS, Tzao C, et al. Comparison of Charlson comorbidity index and Kaplan-Feinstein index in patients with stage I lung cancer after surgical resection. Eur J Cardiothorac Surg 2007; 32(6): 877-81.
48. Woodfield JC, Pettigrew RA, Plank LD, et al. Accuracy of the surgeons' clinical prediction of perioperative complications using a visual analog scale. World J Surg 2007; 31(10): 1912-20.
49. Iversen LH, Norgaard M, Jacobsen J, et al. The impact of comorbidity on survival of Danish colorectal cancer patients from 1995 to 2006-a population-based cohort study. Dis Colon Rectum 2009; 52(1): 71-8.
50. Lubke T, Monig SP, Schneider PM, et al. Does Charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer? Zentralbl Chir 2003; 128(11): 970-6.
51. Baastrup R, Sorensen M, Hansen J, et al. Social inequality and incidence of and survival from cancers of the oesophagus, stomach and pancreas in a population-based study in Denmark, 1994-2003. Eur J Cancer 2008; 44(14): 1962-77.
52. Merrill RM, Merrill AV, Mayer LS. Factors associated with no surgery or radiation therapy for invasive cervical cancer in Black and White women. Ethn Dis 2000; 10(2): 248-56.
53. Dignan M, Michielutte R, Sharp P, et al. The role of focus groups in health education for cervical cancer among minority women. J Community Health 1990; 15(6): 369-75.
54. Thomas V, Richardson A, Saleem T, et al. The efficacy of bilingual health advocacy in ethnic minority patients with cancer. Nurs Stand 2000; 14(26): 32-3.
55. Alcaraz KI, Kreuter MW, Davis KL, et al. On linkages: increasing awareness of and interest in public health and cancer control careers among minority middle school students. Public Health Rep 2008; 123(4): 533-9.
56. Gany FM, Herrera AP, Avallone M, Changrani J. Attitudes, knowledge, and health-seeking behaviors of five immigrant minority communities in the prevention and screening of cancer: a focus group approach. Ethn Health 2006; 11(1): 19-39.
57. Hawthorne K, Robles Y, Cannings-John R, Edwards AG. Culturally appropriate health education for type 2 diabetes mellitus in ethnic minority groups. Cochrane Database Syst Rev 2008(3): CD006424.